Medicare to pay for Myriad's BRCA testing in prostate cancer patients

By staff writers

July 31, 2020 -- Medicare will be covering use of Myriad's BracAnalysis companion diagnostic in men with prostate cancer who may be eligible for treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza).

Lynparza is approved for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. BRCA testing in prostate cancer has been gaining steam with the approval of new indications for Lynparza (Merck/AstraZeneca) and other PARP inhibitors for this tumor type, building on the original approved use for treatment of ovarian cancer.

Copyright © 2020

To read this and get access to all of the exclusive content on, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?